Abstract

The invention concerns a new mutant of .gamma.-IFN. This new polypep-tide contains 134 amino acids. Amino acids 1 to 132 are the same as those of natural .gamma.-interferon. The first amino acid, methionine, in the zero posi-tion is also present, as has been demonstrated by protein sequencing. The amino acid in position 133 is leucine instead of glutamine. The invention also concerns DNA sequences and plasmid DNA (DSM 6238) which codes for this new polypeptide. The invention further concerns the use of the polypeptide as a drug as well as its use as a fine-chemical reagent for in vitro experiments.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (0)

    Publication numberPublication dateAssigneeTitle

NO-Patent Citations (0)

    Title

Cited By (8)

    Publication numberPublication dateAssigneeTitle
    US-6958388-B2October 25, 2005Maxygen, ApsInterferon gamma polypeptide variants
    US-7038015-B2May 02, 2006Maxygen Holdings, Ltd.Interferon gamma polypeptide variants
    US-7230081-B1June 12, 2007Maxygen Holdings, Ltd.Interferon gamma conjugates
    US-7232562-B2June 19, 2007Maxygen Holdings Ltd.E38N interferon gamma polypeptide variants
    US-7390638-B2June 24, 2008Maxygen Holdings, Ltd.S99T C-11 Truncated polynucleotides encoding interferon gamma polypeptide variants
    US-7419805-B2September 02, 2008Maxygen Holdings, Ltd.Polynucleotides encoding S99T interferon gamma polypeptide variants and means of expression
    US-7504237-B2March 17, 2009Maxygen Holdings Ltd.Polynucleotides encoding interferon gamma polypeptides
    US-7524931-B2April 28, 2009Maxygen Holdings Ltd.Full-length interferon gamma polypeptide variants